1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
[CROSSREF] [PUBMED] [PDF]
2. Kwon HJ, Ha YC, Park HM. Prevalence of sarcopenia in the Korean woman based on the Korean National Health and Nutritional Examination Surveys. J Bone Metab 2016;23:23-26.
[CROSSREF] [PUBMED] [PMC]
3. Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, Lowell BB, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000;6:924-928.
[CROSSREF] [PUBMED] [PDF]
4. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2:819-829.
[CROSSREF] [PUBMED] [PMC]
5. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-838.
[CROSSREF] [PUBMED] [PMC]
6. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013;6:25-39.
[CROSSREF] [PUBMED] [PMC]
7. Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia 2009;52:1889-1898.
[CROSSREF] [PUBMED] [PMC] [PDF]
8. Hartwig S, Raschke S, Knebel B, Scheler M, Irmler M, Passlack W, et al. Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014;1844:1011-1017.
[CROSSREF] [PUBMED]
9. Raschke S, Eckardt K, Bjorklund Holven K, Jensen J, Eckel J. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 2013;8:e62008.
[CROSSREF] [PUBMED] [PMC]
10. Jeon YK, Kim SS, Kim JH, Kim HJ, Kim HJ, Park JJ, et al. Combined aerobic and resistance exercise training reduces circulating apolipoprotein J levels and improves insulin resistance in postmenopausal diabetic women. Diabetes Metab J 2020;44:103-112.
[CROSSREF] [PUBMED] [PMC]
11. Komolka K, Albrecht E, Wimmers K, Michal JJ, Maak S. Molecular heterogeneities of adipose depots: potential effects on adipose-muscle cross-talk in humans, mice and farm animals. J Genomics 2014;2:31-44.
[CROSSREF] [PUBMED] [PMC]
12. Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: novel insight into factors, mechanisms, and therapeutics. J Cell Physiol 2017;232:61-68.
[CROSSREF] [PUBMED]
13. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008;88:1379-1406.
[CROSSREF] [PUBMED]
14. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-1489.
[CROSSREF] [PUBMED] [PMC] [PDF]
15. Paula FM, Leite NC, Vanzela EC, Kurauti MA, Freitas-Dias R, Carneiro EM, et al. Exercise increases pancreatic β-cell viability in a model of type 1 diabetes through IL-6 signaling. FASEB J 2015;29:1805-1816.
[CROSSREF] [PUBMED]
16. Lambernd S, Taube A, Schober A, Platzbecker B, Gorgens SW, Schlich R, et al. Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia 2012;55:1128-1139.
[CROSSREF] [PUBMED] [PDF]
17. Giudice J, Taylor JM. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol 2017;34:49-55.
[CROSSREF] [PUBMED] [PMC]
18. Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011;54:846-856.
[CROSSREF] [PUBMED] [PMC]
19. Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 2015;21:403-416.
[CROSSREF] [PUBMED]
20. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013;59:557-562.
[CROSSREF] [PUBMED]
21. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250-259.
[CROSSREF] [PUBMED] [PMC]
22. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014;592:1091-1107.
[CROSSREF] [PUBMED] [PMC]
23. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014;59:1772-1778.
[CROSSREF] [PUBMED]
24. Cesari M, Pedone C, Incalzi RA, Pahor M. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc 2010;11:26-32.
[CROSSREF] [PUBMED]
25. Woo CY, Jang JE, Lee SE, Koh EH, Lee KU. Mitochondrial dysfunction in adipocytes as a primary cause of adipose tissue inflammation. Diabetes Metab J 2019;43:247-256.
[CROSSREF] [PUBMED] [PMC]
26. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver: the link between adipocytes and hepatocytes. Digestion 2011;83:124-133.
[CROSSREF] [PUBMED]
27. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care 2012;15:12-22.
[CROSSREF] [PUBMED]
28. Remelli F, Vitali A, Zurlo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11:E2861.
[CROSSREF]
29. Scott D, Blizzard L, Fell J, Ding C, Winzenberg T, Jones G. A prospective study of the associations between 25-hydroxy-vitamin D, sarcopenia progression and physical activity in older adults. Clin Endocrinol (Oxf) 2010;73:581-587.
[CROSSREF] [PUBMED]
30. Ceglia L. Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 2008;29:407-414.
[CROSSREF] [PUBMED]
31. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011;9:85.
[CROSSREF] [PUBMED] [PMC] [PDF]
32. Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest 2012;42:1189-1196.
[CROSSREF] [PUBMED]
33. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012;55:1103-1111.
[CROSSREF] [PUBMED]
34. Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr 2014;33:737-748.
[CROSSREF] [PUBMED]
35. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 2010;21:543-559.
[CROSSREF] [PUBMED] [PDF]
36. Oh KJ, Lee DS, Kim WK, Han BS, Lee SC, Bae KH. Metabolic adaptation in obesity and type II diabetes: myokines, adipokines and hepatokines. Int J Mol Sci 2016;18:E8.
[CROSSREF]
37. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
[CROSSREF] [PUBMED] [PMC] [PDF]
38. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636.
[CROSSREF] [PUBMED]
39. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34:1323-1328.
[CROSSREF] [PUBMED] [PMC]
40. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
[CROSSREF] [PUBMED]
41. Rubio-Ruiz ME, Guarner-Lans V, Perez-Torres I, Soto ME. Mechanisms underlying metabolic syndrome-related sarcopenia and possible therapeutic measures. Int J Mol Sci 2019;20:E647.
[CROSSREF]
42. Zhang H, Lin S, Gao T, Zhong F, Cai J, Sun Y, et al. Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults: a systematic review and meta-analysis. Nutrients 2018;10:E364.
[CROSSREF]
43. Park BS, Yoon JS. Relative skeletal muscle mass is associated with development of metabolic syndrome. Diabetes Metab J 2013;37:458-464.
[CROSSREF] [PUBMED] [PMC]
44. Kim G, Lee SE, Jun JE, Lee YB, Ahn J, Bae JC, et al. Increase in relative skeletal muscle mass over time and its inverse association with metabolic syndrome development: a 7-year retrospective cohort study. Cardiovasc Diabetol 2018;17:23.
[CROSSREF] [PUBMED] [PMC] [PDF]
45. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-690.
[CROSSREF] [PUBMED] [PDF]
46. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
[CROSSREF] [PUBMED]
47. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273.
[CROSSREF] [PUBMED]
48. Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: a meta-analysis. Saudi J Gastroenterol 2018;24:12-17.
[CROSSREF] [PUBMED] [PMC]
49. Pan X, Han Y, Zou T, Zhu G, Xu K, Zheng J, et al. Sarcopenia contributes to the progression of nonalcoholic fatty liver disease-related fibrosis: a meta-analysis. Dig Dis 2018;36:427-436.
[CROSSREF] [PUBMED]
50. Yu R, Shi Q, Liu L, Chen L. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. BMC Gastroenterol 2018;18:51.
[CROSSREF] [PUBMED] [PMC] [PDF]
51. Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 2018;68:1755-1768.
[CROSSREF] [PUBMED]